Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial al...
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come ...
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
This study is for older children, adolescents, and young adults with B-cell Acute Lymphoblastic Leukemia (B-ALL). Higher amounts of body fat is associated with resistance to chemotherapy in patients w...
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
This pilot trial assesses the effect of the combination of blinatumomab with dasatinib or imatinib and standard chemotherapy for treating patients with Philadelphia chromosome positive (Ph+) or ABL-cl...
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
This study will evaluate the use of non- TBI (total body irradiation) conditioning for B-ALL patients with low risk of relapse as defined by absence of NGS-MRD (next generation sequencing minimal resi...
ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia
This phase I/II trial studies the side effects and best dose of ADCT-602 in treating patients with B-cell lymphoblastic leukemia that has come back or does not respond to treatment. Monoclonal antibod...
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
This is a first-in-human, open-label, dose escalation and expansion study of UCART22 administered intravenously to patients with relapsed or refractory B-cell acute Lymphoblastic Leukemia (B-ALL). The...
Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia
This trial is a limited multi-center, Phase II study to evaluate inotuzumab ozogamicin (Besponsa) in pediatric patients with MRD positive CD22-positive B-lymphoblastic leukemia (B-ALL). Some patients...
Top Cities for B-Cell Acute Lymphoblastic Leukemia Clinical Trials
B-Cell Acute Lymphoblastic Leukemia clinical trials are recruiting across 39 cities. Here are the cities with the most active studies:
About B-Cell Acute Lymphoblastic Leukemia
B-cell acute lymphoblastic leukemia (B-ALL) is a fast-growing cancer of the B-type lymphocyte white blood cells. It is the most common childhood cancer but can also occur in adults. Treatment includes chemotherapy, targeted therapy, and CAR-T cell therapy.
Clinical trials are advancing new treatments for b-cell acute lymphoblastic leukemia. Currently, 8 studies are recruiting a combined 6,156 participants across the United States. Research is being conducted by 7 organizations including Children's Oncology Group, National Cancer Institute (NCI), Etan Orgel and 4 others.
2026 B-Cell Acute Lymphoblastic Leukemia Research Landscape
As of March 2026, the b-cell acute lymphoblastic leukemia clinical trial landscape includes 8 actively recruiting studies across 39 cities in the United States. These studies are collectively seeking 6,156 participants, with an average enrollment target of 770 per study.
Research is being led by 7 different organizations, including Children's Oncology Group, National Cancer Institute (NCI), Etan Orgel, Pediatric Transplantation & Cellular Therapy Consortium, M.D. Anderson Cancer Center, and 2 others.
Geographically, b-cell acute lymphoblastic leukemia trials are most concentrated in Birmingham, Alabama (4 trials); Los Angeles, California (4 trials); Phoenix, Arizona (3 trials); Little Rock, Arkansas (3 trials); New York, New York (3 trials) and 7 other cities.
Featured B-Cell Acute Lymphoblastic Leukemia Studies
Highlighted recruiting studies for b-cell acute lymphoblastic leukemia, selected by enrollment size and research scope.
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin ...
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients with relapsed B-ALL are included in this study. Blinatumomab is an antibody, which is a protein that identifies and targets specific molecules in the body. Blin...
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
This study is for older children, adolescents, and young adults with B-cell Acute Lymphoblastic Leukemia (B-ALL). Higher amounts of body fat is associated with resistance to chemotherapy in patients with B-ALL. Chemotherapy during the first month causes large gains in body fat in most people, even those who start chemotherapy at a healthy weight. This study is being done to find out if caloric re...
Frequently Asked Questions About B-Cell Acute Lymphoblastic Leukemia Clinical Trials
Are there b-cell acute lymphoblastic leukemia clinical trials near me?
Yes, there are 8 b-cell acute lymphoblastic leukemia clinical trials currently recruiting across 39+ cities in the United States, including Birmingham, Alabama; Los Angeles, California; Phoenix, Arizona. Browse the studies above to find one at a location convenient for you.
How do I join a b-cell acute lymphoblastic leukemia clinical trial?
To join a b-cell acute lymphoblastic leukemia clinical trial: 1) Browse the available studies on this page, 2) Click on a study that interests you, 3) Check the study locations to find a site near you, 4) Review the eligibility criteria, and 5) Contact the study site or complete the eligibility form. The process is free and you can withdraw at any time.
Are b-cell acute lymphoblastic leukemia clinical trials free?
Yes, participation in b-cell acute lymphoblastic leukemia clinical trials is free. Study-related treatments, medical tests, and doctor visits are provided at no cost to participants. Many studies also offer compensation for your time and travel expenses.
What types of b-cell acute lymphoblastic leukemia treatments are being studied?
Current b-cell acute lymphoblastic leukemia clinical trials are testing a range of approaches. These include new drugs, combination therapies, medical devices, and other interventions sponsored by 7 research organizations.
Is it safe to participate in b-cell acute lymphoblastic leukemia clinical trials?
Clinical trials are carefully regulated by the FDA and institutional review boards (IRBs). All trials must follow strict safety protocols, and participants receive close medical monitoring throughout the study. You can withdraw from a trial at any time without penalty.
Data updated March 1, 2026 from ClinicalTrials.gov
About This Data
Clinical trial information on this page is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health (NIH) and National Library of Medicine (NLM). Study data is refreshed every hour to ensure accuracy.
Medical Disclaimer: The information provided on this page is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making decisions about clinical trial participation or changes to your treatment plan.
Page reviewed by the HelloStudys Research Team · Last updated March 1, 2026 · Data from ClinicalTrials.gov